An Observational Study on The Correlation Between Time of Initiation of Avastin (Bevacizumab) Treatment And Progression-Free Survival in Patients With Metastatic Breast Cancer (CRONOS 2)
Terminated
- Conditions
- Breast Cancer
- Registration Number
- NCT01277133
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This single arm, prospective, observational study will assess the correlation between the time from start of chemotherapy to the start of Avastin (bevacizumab) treatment with progression-free survival in patients with previously untreated metastatic breast cancer. Patients will be followed for up to 12 months after progressive disease occurs.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 83
Inclusion Criteria
- Adult patients, >/=18 years of age
- Previously untreated metastatic breast cancer
- Scheduled to start 1st line chemotherapeutic treatment
- ECOG performance status 0-1
Read More
Exclusion Criteria
- Any conditions included in contraindication list for Avastin
- Prior chemotherapy for metastatic breast cancer
- Adjuvant/neoadjuvant chemotherapy or radio-chemotherapy of non-metastatic malignancy completed <6 months prior to treatment start
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Correlation between the time from start of chemotherapy to the start of Avastin treatment with progression-free survival 60 months
- Secondary Outcome Measures
Name Time Method Overall survival 60 months Safety: Incidence of adverse events 60 months